Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Cripe

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Pediatric Blood & Cancer|April 25, 2015
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1Edwin Jousma, Tilat A Rizvi, Jianqiang Wu, et al.
Cancer|February 18, 2017
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
Cancer Research|February 19, 2009
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivoTrisha M Wise-Draper, Rachael A Mintz-Cole, Teresa A Morris, et al.
Molecular Cancer Research : MCR|April 10, 2020
Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle DefectsYao Wang, Jeffrey H Stear, Ashleigh Swain, et al.
Cell Reports|July 30, 2023
Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironmentAlessandro Canella, Matthew Nazzaro, Sakthi Rajendran, et al.
Cancer Immunology Research|January 8, 2025
Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast CancerEmily Schwarz, Himanshu Savardekar, Sara Zelinskas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
Immunity|July 21, 2017
The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected CellsHong-Sheng Dai, Nathaniel Griffin, Chelsea Bolyard, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 20, 2007
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft modelYonatan Y Mahller, Sachin S Vaikunth, Mark A Currier, et al.
Pediatric Blood & Cancer|June 20, 2020
Pediatric cancer research: Surviving COVID-19Jeffery J Auletta, Peter C Adamson, Jonathan E Agin, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Pediatric Blood & Cancer|April 25, 2015
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1Edwin Jousma, Tilat A Rizvi, Jianqiang Wu, et al.
Cancer|February 18, 2017
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
Cancer Research|February 19, 2009
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivoTrisha M Wise-Draper, Rachael A Mintz-Cole, Teresa A Morris, et al.
Molecular Cancer Research : MCR|April 10, 2020
Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle DefectsYao Wang, Jeffrey H Stear, Ashleigh Swain, et al.
Cell Reports|July 30, 2023
Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironmentAlessandro Canella, Matthew Nazzaro, Sakthi Rajendran, et al.
Cancer Immunology Research|January 8, 2025
Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast CancerEmily Schwarz, Himanshu Savardekar, Sara Zelinskas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
Immunity|July 21, 2017
The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected CellsHong-Sheng Dai, Nathaniel Griffin, Chelsea Bolyard, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 20, 2007
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft modelYonatan Y Mahller, Sachin S Vaikunth, Mark A Currier, et al.
Pediatric Blood & Cancer|June 20, 2020
Pediatric cancer research: Surviving COVID-19Jeffery J Auletta, Peter C Adamson, Jonathan E Agin, et al.
Pageof 13